Evidence map›Paper›PMID 30366476›Full record

ArticleInternational journal of molecular sciences2018

The Bromodomain Inhibitor

Barbara Siegenthaler, Chafik Ghayor, Bebeka Gjoksi-Cosandey, Nisarat Ruangsawasdi, Franz E Weber

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. The Role of Macrophage in the Pathogenesis of Osteoporosis.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Barbara SiegenthalerCenter of Dental Medicine, Oral Biotechnology & Bioengineering, University of Zurich, Plattenstrasse 11, 8032 Zürich, Switzerland. barbara.m.siegenthaler@gmail.com.
Chafik GhayorCenter of Dental Medicine, Oral Biotechnology & Bioengineering, University of Zurich, Plattenstrasse 11, 8032 Zürich, Switzerland. chafik.ghayor@usz.ch.
Bebeka Gjoksi-CosandeyCenter of Dental Medicine, Oral Biotechnology & Bioengineering, University of Zurich, Plattenstrasse 11, 8032 Zürich, Switzerland. bebeka.cosandey@gmail.com.
Nisarat RuangsawasdiDepartment of Pharmacology, Faculty of Dentistry, Mahidol University, Bangkok 10400, Thailand. nisarat_mac@hotmail.com.
Franz E WeberCenter of Dental Medicine, Oral Biotechnology & Bioengineering, University of Zurich, Plattenstrasse 11, 8032 Zürich, Switzerland. franz.weber@zzm.uzh.ch.ORCID 0000-0003-1670-2296
University of Zurich · CHMahidol University · TH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 31003A_140868
6 · The paper itself

Abstract

(1) Background: In an adult skeleton, bone is constantly renewed in a cycle of bone resorption, followed by bone formation. This coupling process, called bone remodeling, adjusts the quality and quantity of bone to the local needs. It is generally accepted that osteoporosis develops when bone resorption surpasses bone formation. Osteoclasts and osteoblasts, bone resorbing and bone forming cells respectively, are the major target in osteoporosis treatment. Inside bone and forming a complex network, the third and most abundant cells, the osteocytes, have long remained a mystery. Osteocytes are responsible for mechano-sensation and -transduction. Increased expression of the osteocyte-derived bone inhibitor sclerostin has been linked to estrogen deficiency-induced osteoporosis and is therefore a promising target for osteoporosis management. (2) Methods: Recently we showed in vitro and in vivo that NMP (

Indexed as

AnimalsBone Morphogenetic ProteinsCell SurvivalDisease Models, AnimalFemaleImmunohistochemistryMiceOsteocytesOsteoporosisPyrrolidinonesRatsRats, Sprague-DawleyBone Morphogenetic ProteinsN-methylpyrrolidonePyrrolidinonesbromodomainN-methyl pyrrolidoneosteocyteosteoporosissclerostin

Identifiers

PMID30366476
PMCPMC6275050
OpenAlexW2898161472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.